FNN Presentation .. WOW!, page-17

That 40 to 50 dollars your talking about is it’s true value as we speak now , not down the track . Crunch the numbers when you see what Medtronic’s payed for Corvalve 12 years ago and take into account that’s US dollars we’re talking about . Now take into account Corvalves TAVR is vastly inferior to what AVR has here and that the likely hood this TAVR is going to be able to be used on much younger patients . Also take into account some of the Billion dollar companies make surgically implanted valves that will loose market share if this valve is approved for use in younger patients , It’s easy to see it could be a situation that will 3 major companies playing of against each other to aquire AVR along with the ADAPT tech which by the way adds significant value to the aquistition price . Bearing in mind there will be a increase in the register size with new share holders and options being picked up I believe share holders could possibly see a conservative return over $200 ps but I it won’t surprise me if it’s substaintialy higher . This is the reason why I aquired a substaintial holding of AVRO over the last few weeks .